



## ASX Company Announcement

### Dimerix Bioscience shareholders sign sale agreements with Sun Biomedical

**16 June 2015** - The Board of Sun Biomedical Limited is pleased to advise that all shareholders of Dimerix Bioscience have signed share sale agreements for the acquisition of Dimerix Bioscience by Sun Biomedical. The execution of these agreements is a condition precedent for the transaction.

The Company now expects to complete the transaction following shareholder approval at the General Meeting on 30 June 2015 for the acquisition of Dimerix and completion of the tranche two capital raising via the issue of 100m shares at 1 cent.

### About Dimerix

Dimerix Bioscience limited is a public unlisted company developing a new therapy for Chronic Kidney Disease. In addition Dimerix owns a patented drug discovery technology that is able to identify combinations of previously approved drugs and develop them for new medical indications with high unmet need. These combinations will be positioned on market as new medications with underlying IP around the combination use and optimal formulation. Since previously approved drugs have extensive prior clinical use, the clinical development pathway for Dimerix's combination therapies will be significantly shorter.

"We are about to embark on a completely new clinical development strategy, that will allow us to uncover new molecular targets for existing and already approved therapies. Dimerix will have a well-defined pathway to bring more novel treatments for suffering patients and with significantly shorter development times" said Howard Digby, Executive Chairman of Sun Biomedical.

-end-

Howard Digby  
Executive Chairman  
+61 434 987 750